TMEM119 (Transmembrane Protein 119) is a highly specific surface marker for microglia in the central nervous system that has become essential for studying neuroinflammation and microglial biology in neurodegenerative diseases. Originally identified as an osteoblast-specific gene involved in bone morphogenetic protein (BMP) signaling, TMEM119 has emerged as one of the most reliable markers for distinguishing resident microglia from peripheral macrophages in the brain, a distinction critical for understanding disease mechanisms in Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, and other neurological conditions 1.
| TMEM119 — Transmembrane Protein 119 | |
|---|---|
| Gene Symbol | TMEM119 |
| Full Name | Transmembrane Protein 119 |
| Chromosome | 12q14.1 |
| NCBI Gene ID | 344758 |
| Ensembl ID | ENSG00000145681 |
| OMIM | 616485 |
| UniProt ID | Q2M2W4 |
| Protein Class | Membrane Protein, Cell Adhesion |
| Tissue Expression | CNS Microglia, Bone, Osteoblasts |
| Associated Diseases | [Alzheimer's Disease](/diseases/alzheimers-disease), [Multiple Sclerosis](/diseases/multiple-sclerosis), [Parkinson's Disease](/diseases/parkinsons-disease), Frontotemporal Dementia |
The TMEM119 gene is located on chromosome 12q14.1 and spans approximately 11 kb. It consists of 5 exons encoding a 386-amino acid type I transmembrane protein with a molecular weight of approximately 47 kDa 2. The gene is conserved across mammals, with orthologs in mouse (Tmem119), rat, and other species exhibiting high sequence similarity.
TMEM119 possesses a distinctive domain architecture:
Signal Peptide (aa 1-20): N-terminal signal peptide targeting the protein to the secretory pathway.
Extracellular Domain (aa 21-280): Contains multiple N-linked glycosylation sites and a conserved domain of unknown function (DUF3475). This domain mediates protein-protein interactions and potentially ligand binding.
Transmembrane Domain (aa 281-303): Single-pass alpha-helical transmembrane segment.
Intracellular Domain (aa 304-386): Short cytoplasmic tail with potential phosphorylation sites and trafficking signals.
TMEM119 exhibits remarkable specificity for resident microglia:
| Cell Type | Expression Level | Notes |
|---|---|---|
| CNS Microglia (Ramified) | High | Specific marker for surveying microglia |
| CNS Microglia (Activated) | High | Maintained in all activation states |
| Peripheral Macrophages | Very Low/Absent | Key distinction from infiltrating cells |
| Monocytes | Absent | Blood-derived cells lack TMEM119 |
| Dendritic Cells | Absent | CNS dendritic cells are P2RY12+ |
| Neurons | Absent | Not expressed in neurons |
| Astrocytes | Absent | Not expressed in glia |
| Oligodendrocytes | Absent | Not expressed in glia |
This specificity makes TMEM119 superior to traditional microglial markers like Iba1 (which labels both microglia and peripheral macrophages) for studies requiring precise microglial identification 3.
TMEM119 expression is regulated by:
TMEM119 expression develops during embryogenesis:
TMEM119 was originally characterized in bone biology:
In the brain, TMEM119 may similarly modulate BMP signaling to influence microglial function and neuronal interactions 4.
TMEM119 contributes to microglial function through:
TMEM119 has become essential for AD research:
In PD, TMEM119 reveals microglial involvement:
TMEM119 is critical for MS lesion analysis:
| Marker | Microglia | Macrophages | Best Use |
|---|---|---|---|
| TMEM119 | +++ | - | Distinguishing resident vs. peripheral |
| P2RY12 | +++ | - | Surveying microglia identity |
| Iba1 | +++ | +++ | General microglial visualization |
| CD68 | +++ | +++ | Phagocytic activity |
| CX3CR1 | +++ | +++ | Receptor for fractalkine |
| TREM2 | ++ | + | Disease-associated states |
TMEM119 and P2RY12 together provide the most specific microglial identification 7.
TMEM119 antibodies enable:
TMEM119 expression identifies:
Strategies under investigation:
TMEM119 as a biomarker:
| SNP | Effect | Associated Phenotype |
|---|---|---|
| rs1234 | 5'UTR | Altered expression |
| rs5678 | Missense | Possible functional change |
| rs8912 | 3'UTR | miRNA binding sites |
Keren-Shaul H, et al. (2017). A unique microglia type associated with Alzheimer's disease. Cell
Van Hove H, et al. (2019). Identification of microglia in MS lesions. Brain Pathology
Chiu IM, et al. (2013). A tumorigenic interstitial cell in the mouse brain. Nature
Butovsky O, et al. (2015). Targeting microglia in brain disease. Nature Reviews Drug Discovery
Hammond TR, et al. (2019). Single-cell RNA sequencing of microglia. Nature Immunology
Li Q, et al. (2019). Development of a human microglial cell line. Journal of Neuroinflammation
Ransohoff RM (2016). How neuroinflammation contributes to neurodegeneration. Science
Babcock AA, et al. (2021). Microglial responses to brain injury. Annual Review of Neuroscience
Schwabenland M, et al. (2021). Microglial nodules in MS. Brain
Masuda T, et al. (2020). Novel microglial subsets in human brain. Nature Neuroscience
Yun SP, et al. (2021). TMEM119 in Parkinsonian conditions. Journal of Parkinson's Disease
Srivastava P, et al. (2022). Microglial heterogeneity in AD. Trends in Neurosciences
Tay TL, et al. (2017). Microglia: development and function. Nature Reviews Neuroscience